Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

Nature

Volumn 434, Issue 7035, 2005, Pages 907-913

  Gorgoulis, Vassilis G ^a   Vassiliou, Leandros Vassilios F ^a   Karakaidos, Panagiotis ^a   Zacharatos, Panayotis ^a   Kotsinas, Athanassios ^a   Liloglou, Triantafilios ^b   Venere, Monica ^c,d   DiTullio Jr , Richard A ^c,d   Kastrinakis, Nikolaos G ^a   Levy, Brynn ^e   Kletsas, Dimitris ^f   Yoneta, Akihiro ^c   Herlyn, Meenhard ^c   Kittas, Christos ^a   Halazonetis, Thanos D ^c,d  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c WISTAR INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENETIC ENGINEERING; GROWTH KINETICS; MEDICAL PROBLEMS; PULMONARY DISEASES; SKIN;

CHROMOSOMAL INSTABILITY; DNA DAMAGE; DNA REPLICATION; SKIN HYPERPLASIAS;

GENES;

BINDING PROTEIN; CHECKPOINT KINASE 2; DOUBLE STRANDED DNA; GROWTH FACTOR; HISTONE H2A; HISTONE H2AX; P53 BINDING PROTEIN 1; PROTEIN P53; UNCLASSIFIED DRUG; HISTONE; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TP53BP1 PROTEIN, HUMAN;

BIOLOGY; GENETICS; MEDICINE;

ALLELIC IMBALANCE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DYSPLASTIC NEVUS; ENZYME PHOSPHORYLATION; GENE INACTIVATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; HYPERPLASIA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR SUPPRESSOR GENE; XENOGRAFT; CELL TRANSFORMATION; CHROMOSOME FRAGILITY; DISEASE COURSE; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ALLELIC IMBALANCE; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME FRAGILITY; DISEASE PROGRESSION; DNA DAMAGE; DNA REPLICATION; ENZYME ACTIVATION; GENES, P53; GENOMIC INSTABILITY; HISTONES; HUMANS; HYPERPLASIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; PRECANCEROUS CONDITIONS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17244366865     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03485     Document Type: Article

References (30)

1. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutations in human cancers. Science 253, 49-53 (1991).
2. Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316-323 (2004).
3. Halazonetis, T. D. Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer. DNA Repair (Amst.) 3, 1057-1062 (2004).
4. Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13, 1549-1556 (2003).
5. d'Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003).
6. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
7. Gorgoulis, V. G. et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am. J. Pathol. 153, 1749-1765 (1998).
8. Karakaidos, P. et al. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 transcriptional control over hCdt1. Am. J. Pathol. 165, 1351-1365 (2004).
9. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
10. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868 (1998).
11. Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003).
12. Schultz, L. B., Chehab, N. H., Malikzay, A. & Halazonetis, T. D. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151, 1381-1390 (2000).
13. Mochan, T. A., Venere, M., DiTullio, R. A. Jr & Halazonetis, T. D. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 63, 8586-8591 (2003).
14. Huyen, Y. et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 432, 406-411 (2004).
15. DiTullio, R. A. Jr et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nature Cell Biol. 4, 998-1002 (2002).
16. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature doi:10.1038/nature03482 (this issue).
17. Berking, C. et al. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res. 64, 807-811 (2004).
18. Spruck, C. H., Won, K. A. & Reed, S. I. Deregulated cyclin E induces chromosome instability. Nature 401, 297-300 (1999).
19. Lengronne, A. & Schwob, E. The yeast CDK inhibitor Sic1 prevents genomic instability by promoting replication origin licensing in late G1. Mol Cell 9, 1067-1078 (2002).
20. Tanaka, S. & Diffley, J. F. Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev. 16, 2639-2649 (2002).
21. Vaziri, C. et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 11, 997-1008 (2003).
22. Ekholm-Reed, S. et al. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J. Cell Biol. 165, 789-800 (2004).
23. Tibbetts, R. S. et al. Functional, interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev. 14, 2989-3002 (2000).
24. Cortez, D., Guntuku, S., Qin, J. & Elledge, S. J. ATR and ATRIP: partners in checkpoint signaling. Science 294, 1713-1716 (2001).
25. MacPail, S. H., Banath, J. P., Yu, Y., Chu, E. & Olive, P. L. Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-irradiated G1-phase cells. Radiat. Res. 159, 759-767 (2003).
26. Arlt, M. F., Casper, A. M. & Glover, T. W. Common fragile sites. Cytogenet. Genome Res. 100, 92-100 (2003).
27. Casper, A. M., Nghiem, P., Arlt, M. F. & Glover, T. W. ATR regulates fragile site stability. Cell 111, 779-789 (2002).
28. Mao, L. et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med. 2, 682-685 (1996).
29. Wistuba, I. I. et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60, 1949-1960 (2000).
30. Maitra, A. et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am. J. Pathol. 159, 119-130 (2001).